Credit Suisse’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $42.4M | Buy |
214,354
+11,916
| +6% | +$2.18M | 0.04% | 411 |
|
|
2023
Q4 | $34.8M | Sell |
202,438
-6,887
| -3% | -$1.06M | 0.03% | 490 |
|
|
2023
Q3 | $31M | Buy |
209,325
+16,027
| +8% | +$2.9M | 0.03% | 516 |
|
|
2023
Q2 | $42.2M | Sell |
193,298
-94,470
| -33% | -$21.1M | 0.04% | 448 |
|
|
2023
Q1 | $63M | Buy |
287,768
+5,799
| +2% | +$1.26M | 0.06% | 316 |
|
|
2022
Q4 | $58.7M | Buy |
281,969
+16,262
| +6% | +$3.57M | 0.06% | 341 |
|
|
2022
Q3 | $58M | Sell |
265,707
-2,714
| -1% | -$618K | 0.06% | 326 |
|
|
2022
Q2 | $56.3M | Buy |
268,421
+3,784
| +1% | +$806K | 0.06% | 348 |
|
|
2022
Q1 | $64.2M | Buy |
264,637
+5,989
| +2% | +$1.45M | 0.05% | 361 |
|
|
2021
Q4 | $67.4M | Sell |
258,648
-26,598
| -9% | -$6.9M | 0.04% | 510 |
|
|
2021
Q3 | $75.2M | Sell |
285,246
-5,303
| -2% | -$1.45M | 0.04% | 474 |
|
|
2021
Q2 | $71.6M | Sell |
290,549
-170
| -0.1% | -$35.7K | 0.04% | 510 |
|
|
2021
Q1 | $56.4M | Sell |
290,719
-5,824
| -2% | -$1.17M | 0.03% | 653 |
|
|
2020
Q4 | $63M | Buy |
296,543
+16,664
| +6% | +$3.32M | 0.03% | 599 |
|
|
2020
Q3 | $48M | Buy |
279,879
+8,858
| +3% | +$1.64M | 0.03% | 627 |
|
|
2020
Q2 | $52M | Sell |
271,021
-30,916
| -10% | -$5.06M | 0.04% | 519 |
|
|
2020
Q1 | $44.5M | Buy |
301,937
+4,702
| +2% | +$749K | 0.04% | 468 |
|
|
2019
Q4 | $46.1M | Buy |
297,235
+78,258
| +36% | +$11.3M | 0.03% | 595 |
|
|
2019
Q3 | $29.6M | Sell |
218,977
-1,818
| -0.8% | -$238K | 0.03% | 701 |
|
|
2019
Q2 | $26.9M | Buy |
220,795
+35,335
| +19% | +$3.91M | 0.02% | 750 |
|
|
2019
Q1 | $19.3M | Sell |
185,460
-101,232
| -35% | -$10.4M | 0.02% | 889 |
|
|
2018
Q4 | $32.6M | Buy |
286,692
+56,336
| +24% | +$6.04M | 0.03% | 540 |
|
|
2018
Q3 | $26.6M | Buy |
230,356
+22,531
| +11% | +$2.47M | 0.02% | 725 |
|
|
2018
Q2 | $21.5M | Buy |
207,825
+5,368
| +3% | +$543K | 0.02% | 807 |
|
|
2018
Q1 | $19.9M | Sell |
202,457
-16,173
| -7% | -$1.53M | 0.02% | 854 |
|
|
2017
Q4 | $18.5M | Buy |
218,630
+1,437
| +0.7% | +$119K | 0.02% | 920 |
|
|
2017
Q3 | $16.7M | Buy |
217,193
+11,474
| +6% | +$878K | 0.02% | 937 |
|
|
2017
Q2 | $16M | Sell |
205,719
-22,631
| -10% | -$1.62M | 0.02% | 930 |
|
|
2017
Q1 | $16.4M | Sell |
228,350
-10,700
| -4% | -$739K | 0.01% | 939 |
|
|
2016
Q4 | $14.8M | Sell |
239,050
-36,102
| -13% | -$2.21M | 0.01% | 976 |
|
|
2016
Q3 | $17.8M | Buy |
275,152
+2,852
| +1% | +$190K | 0.02% | 879 |
|
|
2016
Q2 | $17.2M | Buy |
272,300
+84,966
| +45% | +$5.01M | 0.02% | 847 |
|
|
2016
Q1 | $10.8M | Sell |
187,334
-43,425
| -19% | -$2.46M | 0.01% | 1064 |
|
|
2015
Q4 | $12.4M | Buy |
230,759
+44,479
| +24% | +$2.51M | 0.01% | 1026 |
|
|
2015
Q3 | $9.49M | Sell |
186,280
-61,306
| -25% | -$3.3M | 0.01% | 1148 |
|
|
2015
Q2 | $14M | Buy |
247,586
+33,414
| +16% | +$2.11M | 0.01% | 1033 |
|
|
2015
Q1 | $15.4M | Buy |
214,172
+37,902
| +22% | +$2.46M | 0.02% | 951 |
|
|
2014
Q4 | $9.88M | Sell |
176,270
-66,041
| -27% | -$3.45M | 0.01% | 1290 |
|
|
2014
Q3 | $11.9M | Sell |
242,311
-16,607
| -6% | -$846K | 0.01% | 1193 |
|
|
2014
Q2 | $13.1M | Buy |
258,918
+66,609
| +35% | +$3.3M | 0.01% | 1213 |
|
|
2014
Q1 | $8.59M | Sell |
192,309
-36,928
| -16% | -$1.66M | 0.01% | 1351 |
|
|
2013
Q4 | $10.8M | Sell |
229,237
-81,316
| -26% | -$4.12M | 0.01% | 1217 |
|
|
2013
Q3 | $16.4M | Buy |
310,553
+66,481
| +27% | +$3.23M | 0.02% | 854 |
|
|
2013
Q2 | $11M | Buy |
+244,072
| New | +$11.6M | 0.01% | 1081 |
|
Other funds holding RMD
Credit Suisse's RMD Position: Q1 2024 in Review
Credit Suisse increased its ResMed (RMD) stake by 5.9% in Q1 2024, buying an estimated $2.18M and bringing the position to 214,354 shares worth $42.4M. The position accounts for 0.04% of the portfolio, ranked #411.
Credit Suisse first reported a position in RMD in Q2 2013 and has held it in 44 quarters since. The position peaked at $75.2M in Q3 2021. 718 funds tracked by Wall St. Rank hold RMD as of Q1 2024.
- Credit Suisse held 214,354 shares of ResMed worth $42.4M as of Q1 2024.
- Credit Suisse bought 11,916 ResMed shares in Q1 2024, an estimated $2.18M.
- ResMed made up 0.04% of Credit Suisse's portfolio in Q1 2024, its #411 holding.
- Credit Suisse first reported a position in ResMed in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's ResMed position peaked at $75.2M in Q3 2021.
- 718 funds tracked by Wall St. Rank held ResMed as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.